Bunzo Matsuura

Professor

Ehime University Graduate School of Medicine
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Year:

2025

Background/Aim Secondary sarcopenia is frequently observed in patients with chronic liver disease (CLD), and simple and practical assessment tools in aging society are limited. This study aimed to develop a risk scoring system based on the geriatric nutritional risk index (GNRI) to identify muscle abnormalities in patients with CLD. Materials/Methods Retrospective analysis was carried out on 1181 Japanese patients with CLD (median age 70 years; male:female = 748:433 and Child–Pugh A:B:C = 1029:129:23). LC was noted in 684. Handgrip strength decline (HGSD) and muscle volume loss (MVL) were evaluated using cutoffs established by the Japan Society of Hepatology. Results The proposed scoring system (SDGS‐L) was developed using logistic analysis. Factors included abnormal GNRI ( 3. Sarcopenia/HGSD/MVL prevalence increased with risk scores: 2.3%/13.8%/7.4%, 8.3%/25.8%/19.7%, 21.2%/29.3%/19.2%, and 37.0%/28.6%/18.0% for low (score 0/1), moderate (score 2), high (score 3), and super‐high (score 4/5) scores, respectively ( p < 0.001). GNRI cutoffs for HGS decline and muscle volume loss were 101.5 (AUC 0.675) and 97.7 (AUC 0.742). Significant correlations of GNRI with HGS and skeletal muscle index (SMI) were observed in males ( r = 0.365)/( r = 0.493) and females ( r = 0.297)/( r = 0.462) (each p < 0.001). Conclusion The SDGS‐L scoring system provides a simple cost‐effective tool for predicting sarcopenia and muscle abnormalities in patients with CLD, enabling early intervention without specialized equipment.

Year:

2025

Aim Dynamic changes in the characteristics of hepatocellular carcinoma (HCC) have been observed owing to the development of antiviral therapies and an aging society. This study aimed to evaluate the clinical features and prognosis of patients with HCC but without liver fibrosis (F0 HCC). Methods From 2000 to 2023, 505 patients with HCC who underwent surgical resection as an initial treatment were enrolled and categorized into the F0 ( n = 59) and fibrosis (F1–4, n = 446) groups based on their liver fibrosis status. Clinical features, tumor factors, and survival outcomes were retrospectively analyzed. Inverse probability weighting with propensity scores was used to control for baseline differences between the groups. Results The proportion of F0 HCC (G1/G2/G3/G4 = 1.3/7.0/13.3/20.0%, p < 0.001) and nonviral (NBNC) HCC cases increased steadily over the study period. Patients in the F0 group were older and more likely to show solitary giant tumors; however, no significant differences were observed in tumor differentiation, microvascular invasion, or intrahepatic metastasis between the groups. After adjusting for baseline characteristics, the F0 group showed significantly improved overall survival and recurrence‐free survival compared to the fibrosis group (adjusted median OS: not achieved vs. 90.6 months, p < 0.001; adjusted median RFS: 67.2 vs. 35.1 months, p < 0.001). Conclusions The increasing prevalence of NBNC HCC has contributed to an increase in the number of F0 HCC cases, demonstrating favorable prognoses post‐curative treatment. Screening strategies tailored to detect F0 HCC are urgently needed to optimize outcomes, particularly for older patients and those with large tumors.

Year:

2025

Objectives: While the effectiveness of metabolic/bariatric surgery has been confirmed, understanding the factors associated with weight loss is paramount for providing guidance in postoperative treatment strategies. Here, we aimed to examine the factors associated with long-term maintenance of weight loss after laparoscopic sleeve gastrectomy (LSG). Methods: This prospective observational cohort included patients who underwent LSG at a single academic health center between January 2017 and June 2022. We examined their body composition using InBody 720 or 770 and analyzed the factors associated with the percentage of total weight loss (%TWL) for 24 months. Results: The median body mass index (BMI) was 38.8 (interquartile range [IQR]: 35.6–46.7) preoperatively, 32.7 kg/m2 (IQR: 28.2–38.7) at 12 months postoperatively, and 33.9 kg/m2 (IQR: 29.1–40.1) at 24 months postoperatively. The lowest BMI was observed at 12 months (p < 0.001 vs. preoperative), followed by a significant increase at 24 months (p = 0.003). However, BMI remained significantly lower at 24 months than preoperatively (p < 0.001). The skeletal muscle mass to fat mass ratio (SMM/FM) was 0.59 (IQR: 0.50–0.71) preoperatively, 0.79 (IQR: 0.58–1.26) at 12 months, and 0.70 (IQR: 0.54–1.05) at 24 months, peaking at 12 months (p < 0.001 vs. preoperative) and decreasing significantly by 24 months (p < 0.001). Nevertheless, the SMM/FM ratio at 24 months remained higher than preoperative values (p < 0.001). Median body weight and %TWL were 86.0 kg and 15.6%, respectively, at 24 months after LSG. The SMM/FM ratio at 12 months was positively correlated with %TWL at 24 months after adjusting for age and sex. Conclusions: The effects of LSG persisted for up to 24 months postoperatively. The SMM/FM ratio 12 months after LSG was associated with the rate of weight loss at 24 months.

Year:

2024

Collaborators (4)

Yoichi Hiasa

Professor

Ehime University

JAPAN
View details

Shinya Furukawa

Prof

Ehime University

JAPAN
View details

Masanori Abe

Ehime University

JAPAN
View details

Teruki Miyake

lecturer

Ehime University Graduate School of Medicine

JAPAN
View details